Pre-market · Oct 8, 8:40 am ET · After hours $11.69 0.00%
Open$11.82
Prev close$11.97
Day range$11.58 – $12.06
Volume344.5K
Market cap$731.58M
P/E (TTM)–
Dividend yield–
DSGN Stock News
Headlines matching Design Therapeutics or the DSGN ticker, most recent first.
Craig-Hallum Maintains Design Therapeutics(DSGN.US) With Buy Rating, Maintains Target Price $22Market news · 4 Aug 2026 · Direct mention
Oppenheimer Maintains Design Therapeutics(DSGN.US) With Buy Rating, Maintains Target Price $21Market news · 15 Jun 2026 · Direct mention
Oppenheimer Maintains Design Therapeutics(DSGN.US) With Buy Rating, Raises Target Price to $21PositiveMarket news · 4 May 2026 · Direct mention
Piper Sandler Maintains Design Therapeutics(DSGN.US) With Buy Rating, Maintains Target Price $20Market news · 27 May 2026 · Direct mention
RBC Capital Maintains Design Therapeutics(DSGN.US) With Buy Rating, Raises Target Price to $20PositiveMarket news · 20 May 2026 · Direct mention
Craig-Hallum Maintains Design Therapeutics(DSGN.US) With Buy Rating, Raises Target Price to $22PositiveMarket news · 19 May 2026 · Direct mention
Piper Sandler Maintains Design Therapeutics(DSGN.US) With Buy Rating, Raises Target Price to $20PositiveMarket news · 29 Apr 2026 · Direct mention
RBC Capital Maintains Design Therapeutics(DSGN.US) With Buy Rating, Raises Target Price to $14PositiveMarket news · 29 Apr 2026 · Direct mention
Craig-Hallum Maintains Design Therapeutics(DSGN.US) With Buy Rating, Maintains Target Price $15Market news · 29 Apr 2026 · Direct mention
Jefferies Initiates Design Therapeutics(DSGN.US) With Buy Rating, Announces Target Price $15Market news · 16 Mar 2026 · Direct mention
Oppenheimer Maintains Design Therapeutics(DSGN.US) With Buy Rating, Maintains Target Price $18Market news · 10 Mar 2026 · Direct mention
RBC Capital Initiates Design Therapeutics(DSGN.US) With Buy Rating, Announces Target Price $14Market news · 10 Mar 2026 · Direct mention
Analysts Offer Insights on Healthcare Companies: Mineralys Therapeutics, Inc. (MLYS), Design Therapeutics (DSGN) and Cartesian Therapeutics (RNAC)TipRanks · 10 Mar 2026 · Direct mention
Oppenheimer Initiates Design Therapeutics(DSGN.US) With Buy Rating, Announces Target Price $18Market news · 7 Jan 2026 · Direct mention
RBC Capital Maintains Design Therapeutics(DSGN.US) With Hold Rating, Maintains Target Price $5Market news · 8 Aug 2025 · Direct mention
Discussion
No comments yet — be the first to weigh in on DSGN.
No comments yet — be the first to weigh in on DSGN.